Skip to main content
Premium Trial:

Request an Annual Quote

Glaxo, First Genetic Trust in SNP Collaboration to Locate Adverse-Event Triggers

NEW YORK, Oct. 10 - GlaxoSmithKline and First Genetic Trust have entered into a broad SNP-related research collaboration to define why some individuals are susceptible to certain serious adverse events, the companies said on Wednesday.

GlaxoSmithKline will sponsor the study and conduct all analyses, while First Genetic Trust will provide its independent secure genetic banking services to store biological samples and medical data.

First Genetic Trust will also ensure that participating patients’ privacy is protected.

“Pharmacogenetic studies such as this one will not only increase patient safety but also provide a scientific basis to understand ADRs at the molecular level,'' Allen Roses, senior vice president of genetics research at GlaxoSmithKline, said in a statement.  

“We expect the collaboration to … contribute to the refinement of our genetic banking services that are available to the clinical research community,” added Arthur Holden, chairman, CEO, and co-founder of First Genetic Trust.

This announcement comes exactly one year after a team of leading researchers from the SNP Consortium, Motorola, and IBM said they planned to create a new company-- now known as First Genetic Trust --to serve as a genetic bank that will hold individual genetic profiles and act as an intermediary between patients, researchers, and healthcare providers.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.